Odonate Therapeutics, Inc. (NASDAQ: ODT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

On December3, 2018, the board of directors (the “Board”) of Odonate Therapeutics, Inc. (the “Company”) appointed Laura Johnson Douglass to the Board and the Audit Committee of the Board to serve until the Company’s 2019 Annual Meeting of Stockholders and until her successor is duly elected and qualified.

Ms. Douglass is the President and Chief Executive Officer of Next Generation Clinical Research Consulting, Inc., a contract research organization servicing the pharmaceutical industry that she founded in 1999. Additionally, Ms. Douglass is the President and Chief Executive Officer of Eufaeria Biosciences, Inc., a biotechnology company that she founded in 2016. Ms. Douglass is a director of La Jolla Pharmaceutical Company. Ms. Douglass is also a founder and director of SB Bancorp, Inc. and Settlers Bank, Inc. Ms. Douglass received a nursing degree from The University of the State of New York-Albany.

Ms. Douglass will receive an annual retainer of $50,000, which will be prorated for her service for the year ending December31, 2018. On appointment, Ms. Douglass was granted an option to purchase 35,000 shares of the Company’s common stock under the Odonate Therapeutics, Inc. 2017 Stock Option Plan. The stock options will vest and become exercisable with respect to 25% of the underlying shares on the first anniversary of her appointment, with the remaining shares vesting in equal monthly installments over the following three years, subject to continued service requirements.